Microporous Zirconium Silicate for Fast Potassium Removal Without pH Shift
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing zirconium silicate compositions used for treating hyperkalemia cause adverse effects such as mixed leukocyte inflammation, acute urinary bladder inflammation, and increased urine pH, along with low cation exchange capacity and crystalline impurities.
Innovation Solution
Development of novel zirconium silicate molecular sieves with a microporous structure composed of ZrO3 octahedral and SiO2 tetrahedral units, optimized for oral administration, featuring enhanced purity, high potassium exchange capacity, and controlled particle size to prevent undesirable entry into the bloodstream.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If zirconium silicate compositions are used to remove potassium ions from the gastrointestinal tract, then potassium exchange capacity is improved, but harmful factors such as inflammation and pH increase occur
Solution Approach 1:
The patent applies parameter changes by precisely controlling the molar ratios of reactants (zirconium source, silicon source, alkali metal source) and reaction conditions (temperature, pH, time) to produce zirconium silicate with optimized pore structure and surface properties. This results in enhanced potassium exchange capacity while minimizing harmful effects like inflammation and pH increase, as the controlled parameters ensure the material interacts gently with biological systems.
Solution Approach 2:
The patent employs composite materials by combining zirconium silicate with specific pore structures and surface modifications to create a material that simultaneously achieves high potassium exchange capacity and biocompatibility. The composite structure includes controlled pore sizes and surface characteristics that enable selective potassium binding while avoiding adverse biological responses.
2Quantity of substance
If particle size is reduced to increase surface area for ion exchange, then potassium exchange capacity is improved, but particles may enter the bloodstream causing harmful effects
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size distribution within a specific range that maximizes surface area for ion exchange while maintaining safety. The controlled particle size parameters ensure sufficient exchange capacity without being small enough to penetrate biological barriers and enter the bloodstream, thus resolving the contradiction between effectiveness and safety.
3Productivity
If cation exchange capacity is increased to enhance treatment effectiveness, then potassium removal efficiency is improved, but crystalline impurities and low purity are introduced
Solution Approach 1:
The patent applies parameter changes by precisely controlling reaction parameters including molar ratios, temperature profiles, pH levels, and reaction time to produce high-purity zirconium silicate with enhanced cation exchange capacity. The optimized parameters minimize the formation of crystalline impurities while maximizing the desired product's exchange capacity, achieving both high productivity and manufacturing precision.
Solution Approach 2:
The patent employs preliminary action by implementing controlled reaction conditions and purification steps during the synthesis process to prevent impurity formation and ensure high purity before the material is used for potassium removal. The preliminary optimization of synthesis parameters ensures that the material achieves high cation exchange capacity without introducing crystalline impurities that would compromise purity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel zirconium silicate compositions effectively remove potassium ions from the gastrointestinal tract without causing side effects like inflammation or pH increase, providing stable and efficient treatment for hyperkalemia.
Implementation Method 1
microporous zirconium silicate compositions that are formulated to remove toxins, e.g., potassium ions
Implementation Method 2
zirconium silicate molecular sieves with a microporous structure composed of ZrO3 octahedral and SiO2 tetrahedral units
Data Source
AI summary
The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.